Abstract
We hypothesized that supplementation with trehalose, a disaccharide that reverses arterial aging in mice, would improve vascular function in middle-aged and older (MA/O) men and women. Thirty-two healthy adults aged 50-77 years consumed 100 g/day of trehalose (n=15) or maltose (n=17, isocaloric control) for 12 weeks (randomized, double-blind). In subjects with Δbody mass<2.3kg (5 lb.), resistance artery endothelial function, assessed by forearm blood flow to brachial artery infusion of acetylcholine (FBFACh), increased ∼30% with trehalose (13.3±1.0 vs. 10.5±1.1 AUC, P=0.02), but not maltose (P=0.40). This improvement in FBFACh was abolished when endothelial nitric oxide (NO) production was inhibited. Endothelium-independent dilation, assessed by FBF to sodium nitroprusside (FBFSNP), also increased ∼30% with trehalose (155±13 vs. 116±12 AUC, P=0.03) but not maltose (P=0.92). Changes in FBFACh and FBFSNP with trehalose were not significant when subjects with Δbody mass≥2.3kg were included. Trehalose supplementation had no effect on conduit artery endothelial function, large elastic artery stiffness or circulating markers of oxidative stress or inflammation (all P>0.1) independent of changes in body weight. Our findings demonstrate that oral trehalose improves resistance artery (microvascular) function, a major risk factor for cardiovascular diseases, in MA/O adults, possibly through increasing NO bioavailability and smooth muscle sensitivity to NO.
Highlights
Arterial dysfunction develops with advancing age and increases the risk for cardiovascular diseases (CVD) [1, 2]
Two key features of arterial aging that increase the risk for CVD include endothelial dysfunction, as characterized by reduced nitric oxide (NO)-mediated endothelium-dependent dilation (EDD), and stiffening of the large elastic arteries [3,4,5]
These findings demonstrate that oral trehalose supplementation has heterogeneous effects on different functional aspects of arterial aging, and may be a novel strategy to improve resistance artery EDD in healthy middle-aged and older (MA/O) adults
Summary
Arterial dysfunction develops with advancing age and increases the risk for cardiovascular diseases (CVD) [1, 2]. Two key features of arterial aging that increase the risk for CVD include endothelial dysfunction, as characterized by reduced nitric oxide (NO)-mediated endothelium-dependent dilation (EDD), and stiffening of the large elastic arteries [3,4,5]. Therapies that inhibit oxidative and inflammatory signaling with age may have the potential to improve arterial function and reduce CVD risk in healthy middle-aged and older (MA/O) adults. In rodents trehalose preserves vascular function in proinflammatory age-associated disease states [15, 17]. Trehalose is emerging as a novel therapy to inhibit oxidative stress and inflammation and restore vascular function in diseases of aging
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
